CDT
Conduit Pharmaceuticals Inc.
NASDAQ: CDT · HEALTHCARE · BIOTECHNOLOGY
$2.25
-8.55% today
Updated 2026-04-29
Market cap
$13.36M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1,177.89
Dividend yield
—
52W range
$2 – $1,754
Volume
0.4M
Conduit Pharmaceuticals Inc. (CDT) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
+152.1%
Most recent quarter
EPS YoY growth
-10664.7%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-13.2%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-12-31 | $-231.44 | — | $1.31 | $1.44 | +9.9% |
| 2025-11-12 | $-13.16 | — | $2.66 | $2.31 | -13.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | — | $-231.44 | — | $2.72B | +152.1% |
| 2025-09-30 | — | $-13.16 | — | $698.22M | +6.6% |
| 2025-06-30 | — | $-5.46 | — | $671.99M | -149.9% |
| 2025-03-31 | — | $-19.86 | — | $624.86M | +16.6% |
| 2024-12-31 | — | $-2.15 | — | $1.08B | — |
| 2024-09-30 | — | $-22,239.67 | — | $654.93M | — |
| 2024-06-30 | — | $-21,866.87 | — | $-1.35B | — |
| 2024-03-31 | — | $-14,510.45 | — | $535.67M | — |
| 2023-12-31 | — | $-4,582.45 | — | — | — |
| 2023-09-30 | — | $-920.88 | — | — | — |
| 2023-06-30 | — | $-16,503.47 | — | — | — |
| 2023-03-31 | — | $9,762.82 | — | — | — |
Frequently asked questions
Has Conduit Pharmaceuticals Inc. beaten earnings estimates?
Conduit Pharmaceuticals Inc. has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports.
How does CDT stock react to earnings?
CDT stock has moved an average of -1.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Conduit Pharmaceuticals Inc.'s revenue growth rate?
Conduit Pharmaceuticals Inc. reported year-over-year revenue growth of +152.1% in its most recent quarter, with EPS growing -10664.7% year-over-year.